Sort   by:  
 Page size 
TranscriptomicsGene expression profiling in psoriatic lesional and non-lesional skin [brodalumab treatment]
To explore the psoriasis phenotype and pathways involved in psoriasis, we characterized gene expression in lesional and non-lesional skin from psoriasis patients. Furthermore, we explored the effects of various doses of brodalumab on lesional skin over time. From each of the 25 psoriasis patients, w...
ORGANISM(S): Homo sapiens 
2014-03-31 | E-GEOD-53552 | biostudies-arrayexpress
GenomicsIL-17RA blockade by brodalumab hidradenitis suppurativa
IL-17RA blockade by brodalumab hidradenitis suppurativa
PRJNA782312 | ENA
UnknownPopulation pharmacokinetics of brodalumab in patients with moderate to severe plaque psoriasis.
Not available
S-EPMC6850607 | biostudies-literature
TranscriptomicsIL-17RA blockade by brodalumab hidradenitis suppurativa
The goal of this study is to characterize the molecular response of HS patients to brodalumab therapy in skin and serum, and to identify biomarkers of treatment response. Ten participants that received 210 mg/1.5mL brodalumab subcutaneously at week 0, 1, 2, 4 and every 2 weeks after were included in...
ORGANISM(S): Homo sapiens 
2022-04-01 | GSE189266 | GEO
UnknownCirculating Brodalumab Levels and Therapy Outcomes in Patients With Psoriasis Treated With Brodalumab: A Case Series.
Not available
S-EPMC9161115 | biostudies-literature
UnknownMalignancy Rates in Brodalumab Clinical Studies for Psoriasis.
Not available
S-EPMC7275023 | biostudies-literature
TranscriptomicsGene expression profiling in psoriatic lesional and non-lesional skin [brodalumab treatment]
To explore the psoriasis phenotype and pathways involved in psoriasis, we characterized gene expression in lesional and non-lesional skin from psoriasis patients. Furthermore, we explored the effects of various doses of brodalumab on lesional skin over time.
ORGANISM(S): Homo sapiens 
2014-03-31 | GSE53552 | GEO
TranscriptomicsMolecular Profile of Interleukin-17RA Blockade by Brodalumab in Japanese Patients with Psoriasis: Results from the ESPRTI study
Brodalumab, an anti-interleukin-17 receptor antibody, is presumed to be effective in psoriasis due to its action on the IL-17 pathway. This study is an analysis of an exploratory intervention study (ESPRIT) conducted in Japanese patients with moderate to severe plaque psoriasis. The efficacy of brod...
ORGANISM(S): Homo sapiens 
2025-12-31 | GSE268958 | GEO
UnknownBrodalumab for the Treatment of Psoriasis: A Review of Phase III Trials.
Not available
S-EPMC4906115 | biostudies-literature
UnknownReal-world Evidence of Brodalumab Safety for the Treatment of Psoriasis.
Not available
S-EPMC12552225 | biostudies-literature
Sort   by:  
 Page size